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Abstract: We investigate translation in biomedicine by exploring how 
researchers supported by the British Pharmacological Society’s Inte-
grative Pharmacology Fund (IPF) have responded to increasing trans-
lational aspirations within pre-clinical animal research. The IPF 
sought to enhance institutional capacities, collaborative practices, and 
personal skills within in vivo research in the quintessentially transla-
tional fields of pharmacology, physiology and toxicology. We identify 
three manifestations of the influence of translational aspirations: 1) 
shifting from the standardisation of animal models to the alignment of 
research on animals with human therapeutic pathways; 2) expanding 
relationalities of care in animal research from a focus on the animal 
body to institutional arrangements around clinical care; and 3) chang-
ing training around research ethics, integrity and good statistical 
practice. Concluding, we discuss the value of working interactively 
with those involved in the changing practices of animal research and 
translation as a means to foster reflexivity about what matters when 
‘training to translate’. 
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1. Introduction  
 
This paper reflects on the changing research practices of in vivo 
pharmacology through the lens of co-produced research carried out 
with the laboratory animal community. In 2016, the British Pharmaco-
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logical Society (BPS) funded us to conduct an evaluation of the impact 
and achievements of the Integrative Pharmacology Fund (IPF), a pro-
gramme that aimed to support animal research and training in phar-
macology, physiology, and toxicology in the UK. This involved carrying 
out interviews with laboratory animal researchers, but also collaborat-
ing with BPS members towards developing a framework for under-
standing the role of in vivo skills and relevant training in the future of 
pharmacology and related research areas. In what follows, we report 
our experiences in this project, with the aim of using them as an empir-
ical ground to identify ways in which translational discourse may affect 
pre-clinical practices of animal research. At the same time, we reflect 
on how the changing understanding of animal research and translation 
in Science and Technology Studies (STS) can contribute to the devel-
opment of laboratory practices within in vivo pharmacology. 
Intellectually, this study is located at the intersection of three evolv-
ing literatures in STS. The first is work on the practices of laboratory 
animal research, which since Lynch’s classic 1988 study has examined 
the material transformations and ethical implications of turning animal 
bodies into scientific data (Lynch 1988). The second is literature on the 
changing dynamics of translational research. Since the early 2000s, 
this has challenged linear models of translation, and instead charted 
the complexities involved in the movement of biomedical research into 
clinical practice (Sunder Rajan and Leonelli 2013). The third is the 
growing literature on engagement in STS, which is increasingly explor-
ing when and whether STS should intervene (Martin 2016) and the 
role of STS in ethics and education (Joyce et al. 2018). What these liter-
atures have in common is an interest in how ‘good’ science is under-
stood and practiced. Animal research always involves scientific and 
moral uncertainties, as researchers and regulators work out “the prop-
er relations between the suffering of the research animal and the 
health of the human” (Dam and Svendsen 2018, 349). The growth of 
translational imperatives in biomedical research (Harrington and 
Hauskeller 2014) is reshaping how these relations are understood, 
adding moral dimensions to the wider collaborations around animal 
research. These collaborations increasingly include social science 
scholars (Davies et al. 2016), who are working with the laboratory an-
imal community to understand the practices of laboratory animal sci-
ence and further both animal welfare and human health. The mutual 
entwining of scientific and ethical practices in the generation of what 
Thompson (2013) calls “good science” increasingly features reflexive 
social science as well.  
In this paper, we exemplify these shifts – and the role played by 
translational imperatives within them – by drawing on our experience 
in working with laboratory researchers and BPS officers towards the 
development of discussions around good practice within in vivo re-
search. We start by exploring the existing STS literatures on animal re-
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search and translation, drawing out the implications of a growing 
translational imperative in animal research for the organisational ar-
rangements of animal research, the roles and relations that are valued, 
and the changing priorities around reproducibility and validity. We 
then introduce our collaborative work and reflect on the potential for 
developing an STS-informed intervention in the practices of transla-
tional animal research in pre-clinical pharmacology, detailing the 
methods used to evaluate and analyse the outcomes of the IPF. On the 
basis of our sustained interactions with biomedical researchers, we 
then identify three ways in which the growing translational aspirations 
have changed pre-clinical animal research practices. Each of these 
shifts provides a space for productive engagement by STS researchers. 
They are: 1) shifting from standardising animal models to aligning re-
search on animals with human therapeutic pathways; 2) expanding re-
lationalities of care in animal research from a focus on the animal body 
to institutional arrangements around clinical care; and 3) the changing 
focus of training around research ethics and integrity, including differ-
ent interpretations of statistical good practice. Concluding, we discuss 
the value of working interactively with those involved in the changing 
practices of animal research and translation as a means to foster re-
flexivity about the relations and practices that matter when ‘training to 
translate’.  
 
 
2. Re-evaluating animal research in translational 
pharmacology 
 
Since Lynch’s (1988) seminal work on how animals in the laborato-
ry are transformed from naturalistic beings into scientific data, there 
has been considerable interest in STS concerning the complex practic-
es of laboratory animal research. Ethnographic research inspired by 
and drawing on Lynch’s study has tended to focus on three different 
dimensions to the work of transforming animals into data, which con-
tribute to what research participants consider ‘good’ animal research. 
These can be characterised as: standardisation, care, and training. 
These dimensions are worth recalling here, for they still describe criti-
cally important aspects of the relations between animals, roles, and re-
sults that are choreographed in the production of meaningful data 
from animal research; and they also help to pinpoint how these imper-
atives have changes over the last thirty years. The organisational ar-
rangements, allocated roles, and nature of affective relations with ani-
mals in the laboratory have all shifted slightly with the growth of trans-
lational practices in biomedical research. Under UK law, all animal re-
search must be licensed by the Home Office (Animals (Scientific Proce-
dures) Act 1986). Only projects with a positive harm-benefit analysis 
are authorised and all research must seek ways to replace animals in 
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their research, reduce the number of animals used, and refine methods 
to reduce suffering and pain – that is, to apply the 3Rs approach of re-
placement, reduction and refinement (Russell and Burch 1959). The 
growth of translational research imperatives is now increasing the at-
tention given to realising research benefits as both a scientific and eth-
ical issue (Davies 2018) and altering the ways by which the 3Rs are 
applied. This is starting to change the way that standardisation, care, 
and training are understood and practiced.  
The first dimension that has characterised the study of laboratory 
animal research in STS are the practices of standardisation in the pro-
duction of ‘good’ laboratory animals. Historical studies on the devel-
opment of animal research throughout the twentieth century and con-
temporary ethnographies of practices in animal research often stress 
standardisation as the route to reliable animal research1. Lynch noted 
that researchers designated particular laboratory animals as ‘good’ or 
‘bad’, observing that “[t]he ‘goodness’ of the animal referred to the 
readability, clarity, congruence with anticipations of what the data 
should look like, and the ease with which it could be treated as a 
standardized member of a cohort” (Lynch 1988, 271). Standardisation 
remains an important consideration in animal research, but the scien-
tific literature is increasingly concerned with questions around the 
standardisation fallacy (Würbel 2000) or how certain forms of stand-
ardisation intensify issues around validity (Richter et al. 2010). STS ac-
counts increasingly talk about how translation is achieved through 
“balancing standardisation and individual treatments” (Dam and 
Svendsen 2018, 349). The unstable experimental humanised mouse 
model generates value as it becomes a “collaborative thing” around 
which new translational conversations can accrue (Davies 2012).  
The second dimension, evident in Lynch’s work and advanced sub-
sequently, has been the STS attention to how animal research is co-
dependent on the provision of ‘good’ animal care (Lynch 1988, 
Holmberg 2011, Bischur 2011, Viteritti 2013). Care is understood as a 
bodily and affective skill that underpins the validity of the data by re-
ducing animal stress and ensuring that animals perform in the requi-
site and desired way. However, for much of the last thirty years, dis-
cussion of the role of animal care has been premised on a division of 
labour between care practices and research practices. Responsibility 
for care has normally been practiced by animal technicians who work 
in the animal research facility, and who provide specialised care for la-
boratory animals and support for the work of principal investigators. 
There were inevitable tensions between these roles, but as Birke and 
colleagues (2007, 117) suggest, “animal technicians and high-ranking 
scientists […] are bonded by shared understandings of what counts as 
‘good’ animal care”. Animal care remains critically important, but its 
scope is expanding in the context of translational research and chang-
ing regulation. Researchers, as well as animal technicians, are having to 
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attend more carefully to animal experience to facilitate translation 
(Friese 2013). There is a growing attention by regulators of animal re-
search to the “culture of care” of an organisation, which is concerned 
with how communication between roles happens within institutions, 
as well as the extent to which wider societal expectations of humane 
animal care are reflected in practice (Davies et al. 2018).  
The third aspect of work on animal research in STS has been a focus 
on what it means to train people to work well with laboratory animals. 
Despret’s (2004) work has been inspirational in drawing attention to 
how training generates the expectations and affects that authorises a 
good experimental performance and what it means to become an ex-
perimentalist (Holmberg 2008). Despret recounts the work of Rosen-
thal (1966), who used students enrolled in a laboratory course in ex-
perimental psychology to explore how their expectations of what kind 
of rat they were working with shaped the rat’s performance in the 
maze. Despret explores how “the expectations of a good experimenter 
have authorized the rat to become competent” (2004, 120), whilst also 
noting how the rat authorises the student to become competent. 
Despret’s work has informed subsequent studies of how becoming a 
good experimenter involves learning to “become with” animals. Yet, 
this too is changing as the expectations of ‘good’ experimental out-
comes shift from the performance of the animal in the apparatus to 
clinical outcomes. Learning with animals remains a vital component of 
translational research practices. Friese has observed how training for 
translational research involved developing the “right ‘touch’ for sur-
gery” (Friese 2013, 133), so that the researcher could now move be-
tween the parts and the whole of the mouse appropriately. The move-
ments required for translation are now more complex: animals may 
have to be made, unmade, and remade as complex circuits of transla-
tion seek to match the performance of the animal to the human experi-
ence or mechanism it seeks to model (Svendsen and Koch 2013; Nel-
son 2018). This happens within experimental practices, but also 
through increasing contestations over the design of experiments and 
their statistical inferences (Würbel 2017).   
As suggested above, these questions around standards, care and 
training are not only dominant strands in the STS literature on animal 
research, but are also growing discussions in the scientific literature. 
These discussions are particularly evident in the literatures around 
translational research and in pharmacology in particular. Pharmacolo-
gy is quintessentially translational in its objectives and practices, as it 
explicitly seeks to bridge the gap between biological knowledge and 
drug development for humans and non-human animals. Yet this pur-
ported translational achievement is increasingly questioned. Discus-
sions of the pharmaceutical ‘pipeline’ are frequently couched in terms 
of a crisis (Sunder Rajan 2017; Murphy 2017), referring to the failure 
of potentially promising new drugs to progress through the different 
Tecnoscienza – 7 (1) 
 
28 
stages of drug discovery and development from pre-clinical laboratory 
research (whether in vivo, in vitro or in silico), through safety and effi-
cacy testing in animals and humans, to clinical trials in human patients. 
To date, this process of attrition has been most visible when drugs 
have failed to show efficacy in human clinical trials, for this is where 
‘failures’ are most public and costly (Freedman, Cockburn and Simcoe 
2015).  
At the same time, there is a growing sense that these problems may 
also be identified and addressed through re-evaluating the practices of 
pre-clinical animal research. While in vivo research has long been posi-
tioned as vital to translational research, detailed discussion of the spe-
cific value and limitations of animal models in furthering clinical ad-
vances is more recent (for example, Collins 2011). Managing failures 
sooner in the drug discovery process may be less expensive and have 
ethical gains in terms of more effective human clinical trials and less 
animal wastage (Ioannidis et al. 2014). Growing debate over the re-
producibility of many studies using animals in research (Academy of 
Medical Sciences 2015) and the failure of drugs tested on animals that 
subsequently enter human trials is further seen by some as a funda-
mental challenge to the ethical justification of biomedical research in 
animals (Pound and Bracken 2014). Researchers and learned societies 
are thus increasingly reviewing the different phases of in vivo research 
to look closely and critically at the practices for translating knowledge 
of disease mechanisms and treatment between species, including 
around validity of animal models, experimental design, reporting con-
ventions and forms of animal husbandry and care (Begley and Ellis 
2012; Concordat on Openness on Animal Research in the UK; Davies et 
al. 2017; Nuffield Council on Bioethics 2005; Osherovitch 2011). This 
raises questions about the operation of animal models, and also about 
the organisation and implementation of institutional models of transla-
tional research. 
The opening up of discussions around animals used as models with-
in the research community offers an opportunity to integrate STS stud-
ies of animal research with STS work on translation. Earlier models of 
translation, which viewed the process of producing tangible outcomes 
from scientific research in terms of a path – bench to bedside – strewn 
with obstacles to be overcome (e.g. Pober, Neuhauser and Pober 2001), 
have now largely been superseded. Many scientists and funders 
acknowledge the complex trajectories involved in translation and the 
challenges of fostering collaborative relations required to sustain in-
teractive research (Collins 2011; Collins and Tabak 2014; Moher et al. 
2016; Zerhouni 2003). Within STS, translation has increasingly been 
tracked and reinterpreted through attending to how knowledge 
moves: developing laboratory research with therapeutic outcomes rel-
evant to humans requires organising and managing translational pro-
cesses so that “biomedical claims, objects and practices” can “move 
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across boundaries” between institutions, disciplines, and species (Sun-
der Rajan and Leonelli 2013, 466). This promotes certain forms of col-
laboration, standardisation and regulation. Furthermore, these move-
ments are not only one-way. The movement between research, safety 
and efficacy testing and clinical trials is increasingly understood as 
non-linear and recursive, constituting what Lewis and colleagues 
(2014) characterise as “circuits of translation”, which involve both ma-
terial flows and conceptual transformations at each iteration (see also 
Crabu 2016 and 2018).  
There is a significant body of work within STS focusing on patterns 
of translational research in genomics (Maienschein et al. 2008), meta-
genomics (Levin 2014), stem cell research (Maienschein et al. 2008; 
Martin, Brown and Kraft 2008; Fagan 2013), neuroscience (Brosnan 
and Michael 2014) and plant science (Leonelli 2013). The complexity 
of translation they indicate can help in developing new ways of think-
ing about the role that animals play in translational research and the 
training required for researchers to facilitate these practices. Stand-
ardisation is no longer the overriding imperative in animal research. 
Translational animal models need to be stable enough to move, but al-
so sufficiently adaptable to be able to encompass the changing under-
standings of disease that happen through circuits of translation (Da-
vies 2012; Dam and Svendsen 2018; Nelson 2018). Care for the animal 
is increasingly seen as not only a shared ethical value, but also an es-
sential component of research, when translation is dependent on 
stress-linked immunological and other responses (Friese 2013; see al-
so Seok et al. 2013). Training has to be opened up to multiply the “the 
body we care for” (Despret 2004), to include attuning to and trans-
forming humans as well as animals. In translational research “scien-
tists calibrate animals against the medical phenomena which they are 
intended to represent. In turn, human medical conditions and the pa-
tients who manifest them have to be calibrated against the rodent 
models” (Lewis et al. 2013, 776).  
The question for this study is how far the changing understanding 
of animal research and translation in STS can contribute to shaping 
these practices in productive ways. In the next section, we discuss the 
methods and context for research that we carried out in collaboration 
with the British Pharmacological Society (BPS) as part of their pro-
cesses for evaluating past funding and developing future training for 
pre-clinical animal research. 
 
 
3. Evaluating the Integrative Pharmacology Fund 
 
This research emerged from a commission, by the BPS, for the au-
thors to evaluate the outcomes of the Integrative Pharmacology Fund 
(IPF). The BPS are a membership charity, whose mission is to promote 
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and advance pharmacology. They have played a role in the develop-
ment of in vivo skills in the UK by driving long-term collaborative 
partnerships and providing funding. The BPS launched the IPF in 2004 
as part of its efforts to address a perceived in vivo skills gap (ABPI 
2005). It was run between 2004 and 2014 by a consortium involving 
the BPS and three major pharmaceutical companies: AstraZeneca, 
GlaxoSmithKline, and Pfizer (see Collis 2006, 2009; Lowe et al. 2016). 
The IPF was led by a steering group comprising representatives of the 
funders. It worked with national funding bodies (the Biotechnology 
and Biological Sciences Research Council, BBSRC; the Medical Research 
Council, MRC; and the Higher Education Funding Council for England, 
HEFCE) to support in vivo education and training. The initial £4 million 
investment in the IPF was used to leverage total support of £22 million 
for in vivo research, education, and training. The IPF thus constituted a 
significant focus for the BPS for over 15 years; was a substantial in-
vestment of both public and commercial funding; and has played an 
important role in shaping the practices, skills and training that have 
defined pharmacology in the UK over the last 15 years. 
The authors were approached to provide an evaluation of the IPF 
because of past experience in working collaboratively with the labora-
tory animal community (Davies et al. 2016). The overall scope and or-
ganisation of the evaluation project was co-produced between Davies, 
Lowe, and Leonelli as independent researchers, Anna Zecharia and Da-
vid Lewis as representatives of the BPS, and BPS member Michael Col-
lis as an independent consultant (following former leadership of the 
IPF). The project was given ethical approval through the University of 
Exeter. Research started with a review of the current literature on in 
vivo skills training through academic and grey literature. Two ques-
tionnaires were delivered to those who received IPF support as a Mas-
ter’s or PhD student (25 were returned) and those who were appoint-
ed to fellowships or staff positions as a result of IPF support (17 were 
returned). These were used to gather basic information and recruit 
participants for semi-structured interviews. Lowe conducted 19 inter-
views with 20 participants. All participants had been, and many still 
were, engaged in work using in vivo research. They were asked about 
how the BPS had supported their work and invited to reflect on the 
changes they made to the design and conduct of experiments through 
this training, including around ethical practice, public outreach and re-
search translation. The transcripts of these interviews were coded us-
ing the qualitative data analysis software NVivo. The evaluation was 
completed through two stakeholder meetings organised by the BPS, 
which provided feedback on the initial findings and enabled the whole 
evaluation team to develop recommendations in conversation with key 
stakeholders. 
The distinct roles of the University of Exeter researchers and BPS 
representatives were negotiated at the start of the project to establish 
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boundaries that protected the independence of key aspects of the re-
search and the identity of research participants. A firewall was con-
structed between the University of Exeter and the rest of the team, en-
suring only the University researchers had access to the full results of 
the questionnaires, including the identity of the respondents. Partici-
pants for the qualitative research interviews were recruited from the 
lists provided by the BPS and sampled by the authors to encompass a 
diversity of thematic research areas, institutional positions, and per-
sonal experiences with the IPF. Of the interviewees, for example: one 
was the head of an Integrative Mammalian Biology centre (an IMB, dis-
cussed in section 4), eight were researchers working as fellows or 
permanent research staff members at IMBs, four encountered the IPF 
as postgraduate students, three worked in senior technical positions at 
IMBs, two were recipients of ‘pump priming awards’, and a further two 
were well-established figures in animal research who were not based 
at IMBs. To enhance the integrity of the data collected, participants 
were promised full anonymity and only anonymised quotes from in-
terview transcripts were shared with the BPS. It was agreed at the out-
set that the data generated in the project would be owned by the BPS 
but could be used by the authors in subsequent publications independ-
ent of the BPS. 
The final evaluation report was jointly agreed. The main body of it 
detailed the empirical material generated, analysed and drafted by the 
University researchers. The introductory material and final recom-
mendations in the report were guided by the requirements of the BPS, 
drawing on the interviews and workshops, and agreed in consultation 
with the BPS council. For the authors, this project constitutes a con-
structive engagement and intervention into science policy in an area 
for which the BPS assumes professional responsibility. It is notable 
that this ‘serviceable STS’ was for an organisation with little executive 
power itself (Webster, 2007), but with an established role in guiding 
norms and standards for its field. The outcomes of the study thus focus 
on how the organisation and practices of translational pharmacology 
can be enhanced through education, training, and reflexive conduct by 
practitioners. The intervention is shaped by the aims and activity of the 
BPS itself, but also the restricted and specific scope of the power and 
influence of that organisation within a wider context of education, 
skills, research and industrial policy and activity. The report was 
launched in December 2016. One of the initial outcomes from this 
work has been the development of an undergraduate core curriculum 
for pharmacology courses in the UK, which was launched in 2018 and 
now has over thirty organisations signed up2. 
This paper has been developed subsequently and separately from 
the commissioned work. The interview transcripts used for the evalua-
tion were further analysed to explore how researchers manage the dif-
ferent accountabilities and changing aspirations in translational phar-
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macology, drawing on coded responses to questions around ‘best prac-
tice’, ‘translation’ and ‘the 3Rs’. In the next section, we draw on this 
material to explore how translational aspirations are changing the 
practices of standardisation, care, and training indicated by earlier 
studies in STS. We show how the work of transforming animals into 
data sources is being recalibrated at an institutional level, changing 
what is valued as ‘good’ science from standardising animals to aligning 
experiments, expanding institutional interactivity, and in deliberations 
around balancing research design with the 3Rs.  
 
 
4. Training to Translate: The Recalibration of Animal Research 
in UK Pharmacology 
 
A key element of the IPF initiative was the establishment of four In-
tegrative Mammalian Biology centres (IMBs) across six UK universi-
ties. These brought together the different disciplines involved in 
pharmacological research, and were involved in employing staff, 
awarding PhDs and establishing Master’s degree courses to build fu-
ture capacity for in vivo skills in pharmacology. The IMBs were intend-
ed to form centres of excellence, with responsibilities for promulgating 
high standards of animal welfare and developing innovative forms of 
research. An important aspect of this was advancing the translational 
potential of research. This involved a series of changes to practice that 
we identify below.  
 
4.1 From Standardising Animals to Aligning Pre-Clinical and Clinical 
Experiments 
 
Different forms of pre-clinical animal research use animal models in 
different ways. While standardised strains are still used for regulatory 
toxicity and safety testing, research into specific human diseases or in-
juries involves the use of ‘bespoke’ animal models created to model 
particular aspects of a disease3. This dual use of animal models leads to 
a diversity of proposed solutions to the problem of enhancing transla-
tion through in vivo research. Some commentators demand greater 
standardisation in research, for example through standardised report-
ing of animal research (Kilkenny et al. 2010), the reduction of bias in 
publications through experimental randomisation and blinding, the 
publishing of negative results (van der Worp et al. 2010), and the de-
velopment of standards for recognising the importance of genetic 
background effects in animal models (Crusio et al. 2009). Others stress 
enhancing sensitivity to local experimental situations and individual 
disease trajectories, including incorporating animal care and environ-
mental enrichment into translational research (Richter, Garner and 
Würbel 2009; Friese 2013), developing more personalised disease 
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models (Davies 2012), or using biomarkers and so-called reverse 
translation methods to move in non-linear ways between animal mod-
els and individual disease trajectories (Garner 2014). These are not 
mutually-exclusive, since standardised reporting and greater experi-
mental variability can work together, but these debates do indicate the 
tensions researchers face in striving for translation in their work.  
In our interviews, researchers talked about how they had increas-
ingly moved away from established ‘gold standard’ models in animal 
research, instead seeking to match experimental and clinical treatment 
regimes. This happens, for instance, when seeking to align in vivo re-
search with clinical trial protocols, and model patient experiences 
alongside disease characteristics. In other words, there has been a sus-
tained attempt to shift research focus beyond the animal body and re-
lated forms of standardisation and control, and towards the circum-
stances and requirements of clinical care and related institutional ar-
rangements. 
Many researchers report making changes to experimental design, 
especially strategies around dosing techniques and levels, to enable 
them to scale up to human clinical studies. Some have suggested that 
there has been a recent shift away from using dose levels in animal re-
search that would generate a statistically meaningful – and thus pub-
lishable – effect, towards asking whether the doses and methods of 
drug application could translate meaningfully to humans, as exempli-
fied by the following quote: 
 
Are they using the animal model that they are working with in the 
correct way? Are they dosing at a dose that you could think of trans-
lating to a human equivalent that would be actually realistic? Are they 
thinking about what route of administration would you be giving it in 
humans in order to actually think about bio-distribution and those 
sort of things quite early on? (Senior researcher at a small university, 
2016) 
 
As pointed out by the same interviewee, sometimes addressing 
these questions means changing experimental protocols in animal re-
search ‘upstream’, to match the likely downstream mode and dose of 
clinical application:  
 
I’ve become increasingly convinced that if you are going to do a 
drug IV [intravenously] then it’s got to be IV in the mouse. […] And 
within the literature I work in, the [mouse model that the interviewee 
works on] is just littered with examples of mice being fed, or whatev-
er, huge quantities of a drug of some sort which is completely unfea-
sible in man, completely unfeasible. That’s very disappointing because 
what we’ve seen historically is clinical trials being developed on the 
basis of the mouse work, but a disconnect where the human receives 
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a fraction of the scaled dose that the mouse got and it’s not surprising 
that it’s not a very successful trial. (Senior researcher at small univer-
sity, 2016) 
 
Further interviewees discussed how the design, validation, and use 
of animal models are themselves modified to produce results of great-
er translational potential. One researcher described a change in use of 
mice models to simulate the human experience of neurodegenerative 
disease, where drug treatment follows diagnosis rather than preceding 
the onset of symptoms: 
  
We wanted to use an animal model and a time course that was go-
ing to be translational. What a lot of previous work does is set up an 
animal model, of Alzheimer’s or Parkinson’s for example, but they’d 
pre-treat it with the drug before the model was initiated. So translat-
ing that to people is effectively like treating anyone over 50 with a 
drug in the hope that a few of them get Alzheimer’s disease. They 
won’t get Alzheimer’s disease because you’ve given them the drug. So 
that was one of the problems in what we were doing. So we sort of 
worked quite hard to design a study so that you set-up the model, 
wait a certain period of time to make the animals how a person would 
be when they get to clinic with Parkinson’s or Alzheimer’s, for exam-
ple, and then that’s when you start the drug treatment. (Postdoctoral 
researcher at large research university, 2016) 
 
Another researcher talked about moving from using adult rats to 
using elderly rats, and small focal lesions to larger ones, to better mod-
el important characteristics of people affected by stroke. As well as 
changing the experimental temporalities through matching older ani-
mals to older patients, they also changed the treatment period to 
match median hospital admissions and facilitate the organisation of 
later clinical trials:  
 
In one of our experiments we were infusing the protein into 
the muscles of the animals for a month after stroke, starting 24 
hours after stroke. He [the clinician] challenged me on it. And he 
said, that’s really interesting, but why would you choose a month, 
because in practical terms it’s really hard to run a clinical trial like 
that, as the majority of our patients discharged, the median stay is 
13 days. […] So he said, you’ve got to find a way to compress this 
down into a timeframe that’s compatible with our patients. (Mid-
career researcher at a large research university with a neighbour-
ing hospital, 2016) 
 
This search for a more ‘translatable’ animal model is recognised to 
have trade-offs. The time involved in allowing disease aetiologies to 
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develop may be expensive, and there may be welfare implications if an-
imals with disease symptoms are used in procedures for longer peri-
ods (as, for instance, in the case of diet-induced obesity in mice). In ad-
dition, outcomes are still uncertain even using the ‘best’ available 
models. Some researchers explained how they were including aspects 
of patient experience in their pre-clinical studies. Examples involved 
modelling co-morbidities in experimental stroke research by using hy-
pertensive rats; and using analgesics on animal models, which better 
represents patient experiences while also promoting animal welfare.  
The increasing interactivity fostered by aspirations for translational 
research is promoting the alignment of drugs, doses, models, and tem-
poralities between pre-clinical research with clinical trials and clinical 
application. The interviews indicate growing acceptance that the eval-
uation of animal models requires revision to include their potential 
translational value (as argued by van der Worp et al. 2010 and Garner 
2014, among others). The specifics of this vary by disease area, and re-
searchers stress how improving translational in vivo research is com-
plex and iterative, rather than a one-way linear process. Several inter-
viewees described collaborations as vital for changing both the exper-
imental design and pharmaceutical agent, so that a viable compound 
can be taken from the laboratory into a clinical trial or clinical setting: 
 
A lot of the drugs I was using in my PhD were quite unstable. 
So I couldn’t give them in drinking water or in their food, for ex-
ample. I had to make up the drug fresh each day and give the ani-
mal an injection. In some of the work we’re doing here, with the 
help of [the pharmaceutical company funding the laboratory] 
we’ve been able to mix the drug for example into the mouse food 
so that they can eat it without having an injection twice a week. 
(Postdoctoral researcher at a large research university, 2016) 
 
Indeed, this trend towards context-specific alignments and equiva-
lences increases the complexity of pre-clinical research data and may 
work against those who view standardisation as a solution to the 
translation gap (Lewis, Hughes and Atkinson 2014). This increasing 
complexity demands renewed attention to how care is practiced in 
translational research, both for animals and for people. 
 
4.2  Caring for Animals; Caring for People 
 
Pre-clinical pharmacologists sit at a critical juncture between basic 
and clinical research. In addition to the experimental realignments 
presented above, this also involves working in new organisational con-
figurations and incorporating new relations of care for research sub-
jects, whether they be humans or non-humans. Interviewees talked 
about needing to be more responsive to the multiple responsibilities 
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involved in developing interdisciplinary research collaborations, thus 
reflecting on the new forms of accountability brought about by bring-
ing laboratory and clinical practices closer together. As Crabu suggests, 
in translational research “the laboratory itself can be re-framed and 
adjusted to render laboratory facts and scientific phenomena congru-
ent with the processes of care and the clinical management of patients” 
(Crabu 2016, 3). This changes where problems are defined, how they 
are framed, and how they might be addressed. 
Throughout the interviews, participants highlighted their efforts to 
develop new relations between basic, pre-clinical and clinical re-
searchers, so as to create the interactive and recursive mobilities be-
tween disciplines that facilitate translation. One interviewee used the 
terminology of ‘back-translation’ to identify this shift. This highlights 
the reversion of the stereotypically linear, bench-to-bedside direction 
of translational research, and acknowledges how researchers are now 
seeking to answer questions coming from clinical care in pre-clinical 
research. In their words: 
 
In the past, mainly my research was based on research which was 
done on animal models and problems that people identified in more 
molecular problems. Now it’s also directed by problems in the clinic. 
So […] I’m more thinking about how problems identified in the clinic 
can be back-translated and how animal models can help answer the 
question. (Early career researcher at a medical school, 2016) 
 
Beyond answering questions generated across basic, pre-clinical, 
and clinical research contexts, the translational mobilities of in vivo re-
search also require understanding how answers are given value and 
statistical significance within different experimental systems. Statisti-
cal measures of biological significance have tended to be domain-
specific and to some extent incommensurable with each other. Given 
this context, informal dialogue between pre-clinical and clinical re-
searchers aids further understanding of the criteria by which answers 
will be deemed to be biologically significant across other domains. Be-
ing involved in translational research means adopting statistical stand-
ards that will protect patients in clinical trials, which are not necessari-
ly the same as those meeting the thresholds for publishing in basic re-
search, as highlighted by the following interview quote:  
 
I am more aware of the clinical research and the types of designs 
for clinical trials, which maybe I wasn’t aware of before. So it’s wid-
ened my knowledge and my circle of reading and I am aware of the 
very stringent criteria there are for clinical trials which there isn’t in 
basic science […] There’s this fallacy that exists where people tend to 
think that an n of 6 is enough for a significant experiment in the ani-
mal world, whereas that’s a ridiculous way of thinking now. The 
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group on stroke, they are far further down this line than I am, so they 
have the pre-clinical stroke models and they work very closely with 
the clinicians, so they have much more dialogue. And so being in-
volved with their lab meetings and in just general tearoom discus-
sions, I’ve become more and more aware of how stringent we need to 
be when, first of all, designing experiments and then doing power cal-
culations but also in interpreting our data as well and determining 
what is or what isn’t biologically significant. (Senior lecturer at a large 
research university, 2016) 
 
This exchange can also go the other way, with clinicians being 
trained in animal use and care. One interviewee, who was appointed 
within an IMB centre to help share expertise on animal research, 
talked about how they were able to introduce clinical researchers to 
the required skills to conduct animal research. Clinicians were guided 
through the process of initiating a project, matched up with potential 
collaborators, and given training to design and conduct experiments 
with them. In their words: 
 
In terms of marrying up clinicians to any in vivo research side, 
things have certainly progressed. Those individuals had never had 
any experience of working in an animal model, but [want to] in order 
to progress their work […]; essentially, they’ll ask, ‘I want to do some 
animal work. Who do I talk to?’ Then they end up talking to me. (Re-
search and technical support at a large research university, 2016) 
 
Some collaboration focused around formal roles allocated via the 
IMB centres, such as the research management role above. Other forms 
of interactivity were brokered through jointly-supervised PhD stu-
dentships, which were “always highly favoured where there were two 
supervisors for different faculties […] which could bring together basic 
and translational skills” (senior manager at a large research university, 
2016). Other collaborations were more informal, facilitated by the co-
location of IMB centres near large teaching hospitals. As one research-
er suggested, informal meetings with a clinical researcher with every-
day experience of patient care had provided advice that would not 
have been available from the literature, but which had affected how 
they designed and conducted their experiments:  
 
We probably meet once or twice a year on average, and he asks 
me what I’ve been doing, and I tell him what I’ve been doing, and he 
explains what the challenges are in translating this kind of thing. He’s 
given me a couple of really good bits of advice which made me think 
about how to do the work that I do. It’s these kinds of little gems of in-
formation that you can’t get from the literature and from chatting 
with your friends. It needs to be someone that works with stroke pa-
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tients every day that can tell you the realities of it. (Mid-career re-
searcher at a large research university with a neighbouring teaching 
hospital, 2016)  
 
These informal collaborations do not involve formal working rela-
tionships and typically they do not result in the clinician being in-
volved in co-authoring publications. Nevertheless, our interactions 
with IPF researchers show that informal collaboration plays an im-
portant role in facilitating access to clinical knowledge that comes from 
day-to-day interactions with patients. Informal collaborations supple-
ment the technical and experimental knowhow developed through cir-
cuits of translation, by helping to identify matters of care in both clini-
cal settings and animal research. 
 
4.3 Reporting, Reproducibility, and the 3Rs 
 
In this final empirical section, we explore how translational expec-
tations in animal research are increasingly intertwined with policy and 
training on research integrity, reproducibility, and applications of the 
3Rs. Training to become a ‘good experimenter’ today means conform-
ing to multiple expectations, whilst navigating a shifting methodologi-
cal landscape in light of the so-called crisis in the reproducibility in bio-
logical research (Academy of Medical Sciences 2015). Researchers in 
pre-clinical academic settings are often working in environments 
where there are career pressures to “win a place in a select few jour-
nals” (Horton 2015, 1380). However, top-ranking journals have been 
criticised for poor reporting of animal research, with few articles con-
taining information on randomisation, blinding, and sample size esti-
mation (Macleod et al. 2015). Training students in pre-clinical pharma-
cology means teaching them to negotiate the pressures and policies 
around research integrity, research reproducibility, and the 3Rs. This 
sort of training rarely appears in the literature on animal research in 
STS but is an increasingly significant part of becoming a good experi-
menter (Leonelli 2017). Producing ‘good’ results may not involve 
working directly with animals but will require making ‘good’ calcula-
tions to get sample sizes right, avoid bias, and be transparent about the 
relationship between hypotheses and data.  
Debates over rigour and reproducibility are particularly acute in in 
vivo research, where underpowered experiments and p-hacking result 
in animals’ lives being wasted (Ioannidis et al. 2014)4. Several initia-
tives are seeking to enhance the conduct of biomedical research 
through improving reporting in academic journals, ensuring rigorous 
grant review, and supporting institutional leadership (Begley and Io-
annidis 2015). The ARRIVE guidelines refer to the reporting of animal 
research and are increasingly incorporated into journal submission 
processes (Kilkenny et al. 2010). The PREPARE guidelines are intended 
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to be used prior to research taking place (Smith et al. 2018). The Na-
tional Centre for the 3Rs (NC3Rs) is developing resources to help in vi-
vo researchers in the UK meet legal requirements to replace, reduce, 
and refine the use of animals in their research. These attempts to 
standardise and harmonise the conduct of experiments and pro-
grammes of research mirror international efforts on care and welfare 
of laboratory animals (see Bayne et al. 2015). They also change the at-
tunement between expectations, animals, and affects that go into train-
ing animal researchers (Despret 2004). These are now mediated 
through written guidelines, checklists, and protocols. These document 
what matters in communicating research quality and animal care, but 
they do not resolve tensions for researchers who have to work out how 
to articulate their research to meet these expectations.  
Our interactions with IPF staff revealed widespread support for the 
3Rs, accompanied by a recognition that overall efforts to reduce animal 
use in research should not be at the expense of the statistical power of 
each experiment. Many had been involved in both teaching and out-
reach activities that prompted them to think about relations between 
research translation and the 3Rs. One researcher had contributed to 
the development of the Experimental Design Assistant5, an online tool 
developed by the NC3Rs to assist the design of experiments. Neverthe-
less, divergence in practice remains. In interviews, we found that re-
searchers talking about the requirements for reporting, reproducibility 
and the 3Rs held different views on the most appropriate experimental 
design for translating in vivo research.  
One researcher, who otherwise sought reduction in the use of ani-
mals in education, argued for increased sample size as a way to im-
prove a study’s statistical significance: 
 
If I decide that a study’s worth doing, I do my sample size calcula-
tions. But then in most cases, for a four-month study I’m talking about 
where you have a significant investment in time and energy, we do as 
many animals as we can in that timeframe. So, we don’t attempt to re-
duce the number of animals, because when we do our sample size cal-
culations, we realise that for all the additional animals we put in we 
increase our ability to detect a benefit of a drug and you reduce the 
chances of getting a false positive by accident. So I don’t actually try to 
minimise my animal use, I just decide which experiments are really 
worth doing well, and doing them properly. And the reason for that is 
I think a lot of the low-hanging fruit is gone now, there are no easy 
stroke therapies that are out there. They’re all going to be most likely 
small effect sizes, modest effect sizes, so you just need to power your 
studies as fully as possible. (Mid-career researcher at a large research 
university, 2016) 
 
Another researcher preferred instead to use smaller numbers of an-
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imals, thus shifting focus to the magnitude of experimental effects: 
 
So if you do an experiment in an animal model with a human con-
dition and you get a small change for the better, that shouldn’t be 
used as a rationale for going into man. You need to see a big change. A 
big change at a rational dose. I do quite a lot of consulting now in the 
neuromuscular field and I’m seeing datasets where I tell the company 
on the basis of this, that drug is not going to be clinically effective be-
cause the change is too small, and yet I’ve seen these programmes go 
through to full clinical development. (Senior researcher at a small 
university, 2016) 
 
Both of the above researchers are concerned with the potential val-
ue of their experiments for future drug development and with ensuring 
that their results are reproducible and useful. Their experimental de-
sign is guided by their understanding of how data deriving from the 
drug achieves translational value in their field. If only marginal effects 
are thought to be possible, then larger sample sizes are used. If larger 
experimental effects can be anticipated, then using smaller sample siz-
es constitutes better practice. Even for people working in similar fields, 
on similar organisms, there are different understandings of what con-
stitute good statistical practices for interpreting results in translational 
research. The extent to which experimental practices are sensitive to 
the concrete translational goals depends not only on the biology, but 
also on the prior history of investigation and therapeutic development 
in the relevant area of research, and the historical constitution of that 
research itself. The expectations between researcher and animals that 
Despret (2004) identifies as vital to producing “good experiments” are 
supplemented by researchers’ interpretations of the technical re-
quirements of translation.  
While the two approaches discussed above come from established 
investigators, there are important lessons here for training early-
career researchers. Future efforts to improve experimental design and 
statistical power would benefit from a better understanding of how re-
searchers interpret the overlapping imperatives around the 3Rs, re-
producibility, and translation in their everyday research practices. 
Again, our research suggests that standardised prescriptions of good 
practice should be approached with caution. Checklists and standards 
need to be supplemented with explicit discussions among pre-clinical 
researchers about the assumptions that they make in their experi-
ments, as well as discussions between pre-clinical and clinical re-
searchers to ensure the applicability of findings across domains. Inno-
vation around translational practices from animal research will not be 
achieved through compliance with reporting policies alone, but also 
requires discussion around the validity and mobility of the data that 
results. Minimum standards in check-boxes at the point of submission 
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of a journal article need to be augmented by opportunities to encour-
age dialogue and reflexivity around research practice. This is exempli-
fied by the very exchanges between STS and animal researchers that 
characterised our collaboration with BPS, and the uptake of the rec-
ommendations produced through these interactions, as discussed be-
low. 
 
 
5. Discussion and Conclusion 
 
Our research with representatives from the four IMB centres fund-
ed by the BPS suggests widespread identification with current transla-
tional research imperatives. It also indicates that translational research 
practices are multi-dimensional and, at times, contested. In this paper, 
we identified and discussed three kinds of ways in which researchers 
who use animals in pre-clinical research are responding to imperatives 
to make their work more translatable. These include moving from the 
standardisation of animals to the alignment of experiments, connecting 
practices of animal care and patient care, and reflexivity in the calcula-
tion of statistical power and the 3Rs. Collectively, these constitute dif-
ferent dimensions through which the researchers with whom we in-
teracted conceived of striving towards translatable science. These sup-
plement the ways in which STS scholars talk about animal research 
and translation. They can also be used to inform the future training of 
animal researchers. In closing, we briefly discuss the practical implica-
tions of these findings for the improvement of in vivo research, and re-
flect on how, through sustained dialogue and reciprocal learning 
across STS and animal researchers, co-produced qualitative research 
can contribute to a productive reframing of how scientific practice is 
enacted, understood and evaluated. 
Applying insights from STS scholarship within the initial evaluation 
of the IPF helped us to contribute concrete recommendations for the 
BPS. Many of these recommendations relate to the increasing complex-
ities found in “circuits of translation” charted above, and sought to 
avoid being prescriptive, focusing instead on ways of enhancing reflex-
ivity and learning across organisations and for individuals. The final 
evaluation report included key recommendations for supporting and 
assessing in vivo education, strengthening networks for sharing good 
practice, recognising the diversity of activities and careers involved in 
translational biomedical research, and enhancing collaboration be-
tween them (Lowe et al. 2016). It also details practical examples, in-
cluding the emergence of new roles for managing and facilitating the 
increasingly complex modes of dialogue and collaboration required for 
translational research.  
The evaluation report also identified some specific challenges and 
opportunities for change. Some of the challenges relate to how transla-
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tional research is changing career structures for scientists. There are 
potential barriers in the credit structures in science which value publi-
cation within discipline-specific journals. The researchers interviewed 
here do not exhibit strong disciplinary affiliations; they conduct prob-
lem-focused research, and some were members of more than one 
learned society. Work tracing the pathways taken by translational re-
search indicate that these results are rarely in the highest impact factor 
journals (Cambrosio et al. 2006). However, regimes of scientific credit 
are evolving to accommodate new forms of publication and patent ap-
plications (see Rasmussen 2014), which are more aligned with transla-
tional researchers’ interests. Some of the opportunities relate to how 
translational research is relocating animal research within a wider 
context of organisational practices and research skills. The new BPS 
core curriculum concerning the use of research animals includes train-
ing that puts knowledge, skills and attitudes about animal research in-
to context. However, it no longer requires undergraduate students to 
undertake hands-on research with animal in education settings6. This 
decision was part of the harm-benefit analysis around the use of ani-
mals in education that the report facilitated, suggesting that learning 
outcomes at this stage could be achieved through observation, using 
simulations or videos, or through working with an animal facility 
where research is ongoing.  
Our study adds further dimensions to the accounts of what consti-
tutes ‘good’ animal research in STS with which we started. Striving for 
good translation can be understood through the notion of “good sci-
ence” developed by Charis Thompson, in which scientific and ethical 
practices are understood to be “mutually entwined” (Thompson 2013). 
Thompson’s articulation of good science centres on stem cell research, 
where she argues that “ethical concern lies at the heart of innovation” 
(Thompson 2013, 221). In the case of pre-clinical animal research, 
striving towards translation involves raising questions about model 
reproducibility and validity, rather than standardisation; connecting 
care for animals with care for patients; and balancing the reduction in 
harms to animals with the potential benefits in clinical practice. These 
questions about the planning, conduct, and outcomes of scientific re-
search are important in driving innovative practices but cannot be re-
solved by adhering to (external) ethical guidelines and norms. Training 
for ‘good’ animal research requires attuning experiments to complex 
contexts, learning what matters to different bodies, and interpreting 
statistics and ethics in situ. Many researchers valued taking part in this 
research as an opportunity to reflect on their experiences of being 
trained, developing research careers, and informing the next genera-
tion of pre-clinical pharmacologists. Their accounts of what makes 
good pre-clinical animal research links science and ethics, encom-
passes policy and politics, and draws on individual beliefs and conduct. 
Good translation is enhanced by this reflexivity. The recommendations 
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to the BPS aim to generate researchers able to construct their research 
practice and collaborations in ways that support the multi-directional 
forms of attention that support translational research. Working collab-
oratively with social scientists has helped to identify and enhance 
these opportunities in future training for translation.  
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